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We investigated the effect of selection pressures on evolution of HIV-1 pol in 51 patients after switching to a new antiretroviral
combination reverse transcriptase (RT) inhibitor therapy. Evolution of the protease (PR) and RT reading frames were analysed
separately. Pairwise evolutionary distances (ED) were calculated between sequences from baseline and week 8 and between
baseline and week 48 of protocol therapy. ED were calculated for all substitutions and for synonymous and nonsynonymous
substitutions separately. At week 8 when HIV RNA reduction (selection pressure) was high, significantly more divergence in pol
in both synonymous and nonsynonymous substitutions was found in patients with substantial RNA reduction (strong responders).
Separate analyses of PR and RT revealed significantly greater ED in the RT (under selection pressure) of strong compared with
nonresponders, whereas divergence between PR genes (not under selection pressure) did not differ in those two groups. Such
differential evolution indicates that PR and RT were genetically unlinked and suggests recombination. The rapid increase of ED
over the first 8 weeks was followed by only a minimal further rise by week 48, suggesting that selection of preexisting quasispecies
accounted for the early changes. A disproportionally high number of synonymous substitutions accounted for the observed
divergence and indicated that such genetic changes may not be completely silent. © 1999 Academic Press
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aINTRODUCTION
The genetic plasticity of HIV-1 is key to its persistence
n the infected host (Nowak et al., 1991; Coffin, 1992,
995; Wain-Hobson, 1993) both in the face of naturally
ccurring host responses and in the setting of treatment
ith antiretroviral drugs. Although factors permitting the
eneration of viral genetic diversity have been identified,
hose resulting in viral escape in response to selective
ressures in vivo remain poorly characterized.
Slower disease progression has been correlated with
igher levels of viral diversity of the HIV-1 envelope gene
n adults (Wolinsky et al., 1996; Delwart et al., 1997),
nfants (Salvatori et al., 1997) and children (Ganeshan et
l., 1997). The finding that nonsynonymous substitutions
ere more frequent in slow than in rapid progressors
mplied that greater host immune pressure led to greater
iversity of the env region. In one study, viral diversity in
nv was interpreted as correlating with the vigor of mea-
ured CTL responses (Wolinsky et al., 1996), but others
1 To whom reprint requests should be addressed at University Hos-
ital of Zu¨rich, Department of Internal Medicine, Division of Infectious
iseases, Ra¨mistrasse 100, CH-8091 Zu¨rich, Switzerland. Fax: 41 1 255t291. E-mail: huldrych.guenthard@dim.usz.ch.
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154ave pointed to the relative paucity of data linking CTL
ctivity specific to env with the observations regarding
equence diversity in env (Nowak et al., 1996). Recently
e described higher evolutionary distances (ED) in HIV-1
ol developing in two patients under the strong selection
ressure of triple antiretroviral therapy, including a pro-
ease (PR) inhibitor for 1 year, that was greater than
hose seen in three patients treated with less effective
ouble nucleoside RTI therapy for the same time period
Gu¨nthard et al., 1997). In that study pairwise ED were
enerated by comparing population based sequences
erived from baseline plasma HIV RNA with plasma and
ymph node RNA sequences obtained after 1 year of
herapy. The pattern of ED was the same in plasma and
ymph node, reflecting the apparent equilibrium between
hese compartments (Wong et al., 1997a; Gu¨nthard et al.,
998a). These data suggested that greater genetic diver-
ity of HIV-1 env under presumptively higher selection
ressure imposed by the immune system in studies of
atural history of HIV-1 may have a correlate in higher
enetic diversity of HIV pol with greater selection pres-
ure of antiviral drugs. The selection pressures of anti-
etroviral drugs can be characterized both by their target
nd the quantitative impact of their activity in contrast tohose imposed by the immune system upon envelope. In
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155SELECTION PRESSURE AND HIV polddition, the analysis of HIV-1 pol permits comparison of
djacent reading frames, encoding PR and RT, when one
s subjected to selection pressures and the other one is
ot.
We studied viral evolution of HIV-1 pol in relation to the
evel of plasma HIV-1 RNA reduction in response to
ombination nucleoside RT inhibitor therapy in 51 HIV-1-
nfected patients (D’Aquila et al., 1996) by comparing 124
opulation-based sequences at baseline, week 8 and
eek 48. Several questions were addressed: does ap-
lication of stronger selection pressure on HIV pol result
n greater genetic divergence? If greater viral divergence
ccurs in this setting, will it be due only to changes in
rotein coding sequences (nonsynonymous substitu-
ions) or will synonymous changes also be selected?
oes application of selection pressure on the RT result
n greater divergence in this gene alone, or will higher
ivergence also be found in the adjacent PR?
RESULTS
equences and patient baseline characteristics
One hundred and twenty-seven sequences derived
rom proviral DNA from viral cultures were obtained from
2 patients. Of those, 124 sequences (98%) from 51
atients formed individual clusters of two (baseline/week
or baseline/week 48) or three sequences (baseline/
eek 8/week 48) for each patient when phylogenetic
nalysis was performed (bootstrapped, neighbour-join-
ng tree, data not shown). Three sequences were ex-
FIG. 1. The RNA response at week 8 correlated with the evolutionary
istribution, the RNA response was expressed as log10 (plasma RNA
istances were transformed to squareroot values.luded because of possible laboratory contamination: (ne sequence (from week 48) clustered together with the
equence from pNL4–3 and two sequences of one pa-
ient did not cluster together. All other sequences were
istinct from laboratory strains (pNL4–3, HIV LAI, HIV
XB2). Baseline characteristics from the 51 patients se-
ected for this study (40 on AZT/3TC/Nevirapine, 11 AZT/
DI therapy) corresponded well to the group in the
riginal study (D’Aquila et al., 1996) receiving the triple
ombination therapy. The median CD4-count of the 51
atients analysed was 122 cells/mm3 (CD4%: 9). This
as somewhat lower than the median of 135 CD4-cells/
m3 (CD4%: 11) reported for the triple combination ther-
py arm as a whole (D’Aquila et al., 1996), but this
ifference was not statistically significant. The median
aseline RNA value from the 51 patients of 6.8 3 104 RNA
opies/ml was similar to the one reported for the entire
riple combination group (6.9 3 104 RNA copies/ml)
D’Aquila et al., 1996). Medians for all 398 patients in-
luded in the original study were as follows: CD4-count
37 cells/mm3 (CD4%: 11) RNA baseline 6.4 3 104.
orrelation of synonymous and nonsynonymous
ubstitutions to the RNA response
A log transformation of the HIV RNA values was per-
ormed to obtain a normal distribution. The plasma HIV-1
NA response was expressed as the ratio of HIV-1 RNA
aseline divided by the HIV-1 RNA level at week 8 or 48.
significant positive correlation between an increasing
lasma HIV-1 RNA response and synonymous changes
2
es based on synonymous substitutions at week 8. To obtain a normal
t baseline/plasma RNA level at week 8) and values of evolutionarydistanc
level ar 5 0.2, P 5 0.01) was found in the RT (Fig. 1) at week
8
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156 GU¨NTHARD ET AL., whereas correlations were not found for either non-
ynonymous changes in the RT or for synonymous or
onsynonymous changes in the PR and the RT at Week
8 (Table 1).
volutionary distances (ED)
We hypothesized that ED would be greater in pa-
ients with stronger RNA reduction in viral load. We
herefore compared ED from the quartile of patients
ith the strongest decrease in plasma HIV-1 RNA at
eek 8 (strong responders; mean: 25.5 3 105, range:
5.4 3 104 to 22.7 3 106) with those from the quartile
ith the highest RNA rise (nonresponders; mean:
1.9 3 105, range: 16.7 3 103 to 12.3 3 105, P
0.001) (n 5 8 in each quartile, all 16 patients re-
eived ZDV, ddI, NVP) and week 48 (n 5 11 in each
uartile, 8 of strong and 9 of nonresponders received
DV, ddI, NVP). The baseline characteristics are sum-
arized in Table 2. At week 8, the means of the overall
istances of HIV pol (EDs1n 5 0.019) and of the syn-
nymous distances (EDs 5 0.031) for responders were
T
Correlation of Synonymous and Nonsynonymous Ch
RNA response n
Synon
cha
atio: log10 (RNA at baseline/RNA at week 8) 32
r2 0.0
P value 0.5
atio: log10 (RNA at baseline/RNA at week 48) 41
r2 0.0
P value 0.8
Note. r2 values were calculated by using linear regression and P va
T
Baseline Characteristics between the Quartile
Strong r
hanges in plasma RNA baseline—Week 8 25.5 3 10
(RNA copies/ml)
lasma HIV RNA load (log10 RNA copies/
ml)
Week 0 5.6
Week 8 4.9
bsolute CD4 count, cells/mm3
Week 0 45
ercent CD4 count
Week 0 5.3
Note. Values shown are means followed by medians in brackets.
a Wilcoxon rank-sum test.
b Student’s t test.ignificantly higher than those from the non-respond-
rs (EDs1n 5 0.01, EDs 5 0.016; P , 0.02 and P , 0.02,
espectively). Furthermore nonsynonymous distances
rom the responders also were higher (EDn 5 0.007)
han from the nonresponders (EDn 5 0.004, P 5 0.05)
Fig. 2). When a similar analysis was done including all
atients at week 8, differences in ED between patients
ith a decrease (n 5 22) and an increase (n 5 9) of
lasma RNA were significant for synonymous changes
P 5 0.01) and borderline significant for nonsynony-
ous changes (P 5 0.1). When distances from the
trongest and weakest responders at week 48 (n 5 11
ach) were compared, the same pattern was found but
he difference was not significant. This can be ex-
lained by a smaller difference in RNA response at
eek 48 between responders (mean: 23 3 105, range:
4.1 3 104 to 21.1 3 106) and nonresponders (mean:
1.8 3 105, range: 14.2 3 104 to 13.4 3 105). Analysis
f ED using Kimura 2-parameter distances (data not
hown) gave results similar to overall distances pre-
ented here.
with the RNA Response at Week 8 and at Week 48
Protease Reverse transcriptase
Nonsynonymous
changes
Synonymous
changes
Nonsynonymous
changes
0.05 0.2 0.02
0.21 ,0.02 0.5
0.0002 0.015 0.01
0.9 0.44 0.7
using analysis of variance. n values are sequences.
ng Responders and Nonresponders at Week 8
ers Nonresponders P value
8
3 105] 11.9 3 105 [11.1 3 105] 0.001a
4.7 [4.8] 0.002b
5.2 [5.2] 0.1b
95 [70] 0.2b
7.8 [6] 0.4bABLE 1
anges
ymous
nges
2
01ABLE 2
of Stro
espond
8
5 [21.7
[5.4]
[4.9]
[29]
[3.5]
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157SELECTION PRESSURE AND HIV polistance analysis of RT and PR coding sequences
Comparison of all sequences (Fig. 3). When all 73
equences were compared with the 51 available base-
ine sequences, the mean overall distance of the RT was
Ds1n 5 0.02 and significantly higher than the EDs1n for
he PR, which was 0.013 (P , 0.0001). Synonymous
ubstitutions occurred significantly more frequently in
FIG. 2. Mean evolutionary distances of HIV-1 pol from patients displ
T inhibitor combination antiretroviral therapy. Densely hatched bars:
uartile of weakest responders (n 5 8).
FIG. 3. Mean evolutionary distances (n 5 73) analysed separately for
ars represent distances generated for the protease and sparsely hatched bhe RT (EDs 5 0.03) than in the PR gene (EDs 5 0.019, P ,
.001). Nonsynonymous mutations were also found to
merge significantly more often in the RT (EDn 5 0.009)
ompared with the PR gene (EDn 5 0.005, P , 0.0001).
Comparison of strong vs weak responders at week 8
Fig. 4). The PR-coding sequence, not under selective
ressure in these patients, evolved little during the treat-
trongest and weakest RNA response 8 weeks after switching to new
of patients with strongest response (n 5 8). Sparsely hatched bars:
tease and for the RT gene from all patients (n 5 51). Densely hatchedaying s
quartilethe pro
ars shows distances from the RT.
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158 GU¨NTHARD ET AL.ent period in comparison with RT against which strong
elective pressures were imposed. At week 8, the quar-
ile with the strongest HIV-1 RNA response (n 5 8)
howed the highest number of synonymous substitutions
FIG. 4. (A) Comparison of mean evolutionary distances for the RT at
atched bars) (n 5 8 each). (B) Comparison of mean evolutionary dista
onresponders (sparsely hatched bars) (n 5 8 each).n the RT gene (EDs 5 0.037) compared with the 25% with ehe weakest response (EDs 5 0.012, P , 0.002, Fig. 4A).
n the PR gene, synonymous distances were slightly
ower in the strong responders (EDs 5 0.018) compared
ith the weak responders (EDs 5 0.025, Fig. 4B); how-
between strong (densely hatched bars) and nonresponders (sparsely
r the protease at week 8 between strong (densely hatched bars) andweek 8
nces fover, this difference was not statistically significant (P .
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159SELECTION PRESSURE AND HIV pol.6). With regard to nonsynonymous mutations, strong
esponders again revealed greater distances in the RT
ene than nonresponders (EDn 5 0.008 vs 0.004, P 5 0.1,
ig. 4A). Nonsynonymous distances in the PR gene were
ot significantly higher in strong responders (EDn 5
.005) than in nonresponders (EDn 5 0.003, P . 0.6).
Direct comparison between PR and RT of strong re-
ponders at week 8 (Fig. 5). The overall distance in the
T (EDs1n 5 0.22) was significantly higher than in the PR
EDs1n 5 0.011, P , 0.03). This difference was mainly due
o the higher rate of synonymous changes found in the
T (EDs 5 0.037) compared with the PR gene (EDs 5
.018, P , 0.03). Nonsynonymous mutations were also
ore frequent in the RT (EDn 5 0.008) compared with the
nes in the PR (EDn 5 0.005) but this difference was not
ignificant (P . 0.3).
Comparison between PR and RT of nonresponders at
eek 8 (Fig. 5). In contrast to the strong responders,
hanges in PR (EDs1n 5 0.014) compared with RT (EDs1n
0.008, P . 0.4) in nonresponders at week 8 were not
ignificantly different; nor were significant differences in
ynonymous or nonsynonymous substitutions seen be-
ween PR and RT.
ED from strong and nonresponders at week 48. Among
trong and nonresponders at week 8 with available se-
uence data for generation of week 48 ED, the patterns
een at week 8 persisted at week 48. EDs and EDn in RT
f strong when compared with RT of nonresponders
ere greater. Moreover, EDs and EDn of the RT of strong
FIG. 5. Comparison of mean evolutionary distances for the protease
ensely hatched bars: protease distances from responders. Sparsely
rom nonresponders. Black bars: RT distances from nonresponders.esponders were also greater than the ED of the pro- wease. ED (data not shown) were on the same order as
hose displayed in Table 4 for week 8 ED. However,
tatistical significance was not achieved mainly because
nly five and seven isolates were available at week 48
rom the original quartile of strong (n 5 8) and nonre-
ponders (n 5 8), respectively.
nalysis of Y181C mutation in RT in relation to
volutionary distances at weeks 8 and 48
The mean overall distance between isolates at week 8
EDs1n 5 0.016) was almost as large as at week 48 (EDs1n
0.017). To examine the hypothesis that rapid evolution
y week 8 was due to selection of preexisting quasispe-
ies with considerably different sequences from the
aster sequence that was present at the time therapy
as switched, we investigated the proportion of isolates
hat carry the rapidly emerging nevirapine drug resis-
ance single point mutation Y181C (Richman et al., 1994;
ei et al., 1995; Havlir et al., 1996) present at 8 weeks
nd at 48 weeks in patients who received the NVP-
ontaining regimen. By week 8, 31% of patients already
arbored the Y181 C mutation in their viral sequences
Y181C: n 5 10; Y181: n 5 21), a frequency that increased
ver the next 40 weeks to 53% by week 48 (Y181C: n 5
6; Y181: n 5 14). There was a significant increase of
on-synonymous distances in the RT (week 8: EDn 5
.007; week 48: 0.01, P , 0.01) in the absence of a
arallel rise of synonymous mutations between 8 and 48
e RT at week 8 between strong and weak responders (n 5 8 each).
bars: RT distances from responders. Open bars: protease distancesand th
hatchedeeks (week 8: EDs 5 0.03, week 48: 0.03). These pat-
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160 GU¨NTHARD ET AL.erns are most consistent with the rapid selection of
reexisting mutants between weeks 0 and 8 (Coffin,
995; Najera et al., 1995; Havlir et al., 1996) and a slower
ccumulation of de novo mutations between weeks 8
nd 48.
ifferences between mutations associated with drug
esistance in the RT gene of patients under high
nd low selective pressure
Amino acid residues with mutations known to confer
esistance to ZDV (41 67 70 210 215 219), ddI (65 74 75
84), and NVP (98 100 103 106 108 181 188 190) (Schinazi
t al., 1997) were examined at week 8 in the eight strong
nd the eight nonresponders. At baseline, the two
roups did not harbor resistance mutations with different
requencies (data not shown). At week 8, in contrast to
hat was expected, nonresponders did not develop
ore mutations associated with drug resistance (13 mu-
ations) than strong responders (14 mutations). In each
roup, three new mutations associated with ZDV resis-
ance and 10 mutations associated with NVP resistance
volved. In addition one ddI mutation emerged in a
trong responder. Table 3 shows detailed stratification
ccording to the number of strong and nonresponders
arboring mutations. No mutations at position 62, 75, 77,
16, and 151, which are associated with multiple drug
esistance in patients treated with combination nucleo-
ide RT inhibitors were found (Shirasaka et al., 1995;
versen et al., 1996). Both groups were equally treated
ith ZDV, ddI, and NVP. The lack of a detectable differ-
nce in mutation rates associated with resistance
gainst the drugs used between strong and nonre-
ponders at week 8 suggests that factors other than
ucleotide changes known to be associated with resis-
ance may play a role in the extent of RNA-response
T
Emergence of Mutations Associated with Drug Resistan
and Nonresp
o. of mutations associated with
drug resistance identified in the
same patient isolate
No. of pa
Strong respo
NRTI-resistancea
0 6
1 1
2 0
3 1
Note. n 5 8 patients for strong and nonresponders.
a Nucleoside reverse transcriptase inhibitor resistance to ZDV (41 67
b Nonnucleoside reverse transcriptase inhibitor resistance to NVP (9uring drug treatment. patio nonsynonymous vs synonymous mutations
Table 4)
The ratio of nonsynonymous/synonymous substitu-
ions (pn/ps) was 0.26 for HIV pol when all 124 evaluable
equences from 51 patients were analysed. The ratio for
IV pol rose between weeks 8 (0.24) and 48 [0.32 (Table
)]. When examining the RT and PR gene separately, it is
articularly notable that the ratio in the PR gene does not
hange over time, whereas RT shows an increase of the
atio from 0.23 at week 8 to 0.33 at week 48. At week 8,
ontrary to what might be expected, pn/ps for the RT was
nly 0.22 for the strong responders compared with 0.33
or the nonresponders. However, for the absolute mean
istances, the EDn increased twofold in the strong com-
ared to the nonresponders whereas the EDs rose three-
old. Thus the low ratio for the strong responders at week
is due to a disproportionately high number of synony-
ous changes rather than to a lack of increase in non-
ynonymous changes.
DISCUSSION
The greater sequence divergence seen in HIV pol in
atients under strong selection pressure (defined as
reater reduction in HIV-1 plasma RNA and lower HIV-1
NA nadir at week 8, Table 2) is analogous to reports
escribing greater diversity in env of virus isolated from
atients with slow disease progression compared with
apid progressors (Wolinsky et al., 1996; Delwart et al.,
997; Ganeshan et al., 1997; Salvatori et al., 1997). Those
tudies postulated that genetic diversity in env was
riven by selection via host immune response. In the
resent study, the source of selective pressure and the
iming of its application are known.
That the overall ED between isolates was nearly as
igh at week 8 as at week 48 reflects the rapid shift in
uasispecies composition that can occur when selection
inst ZDV, ddI, and NVP between the Quartile of Strong
at Week 8
arboring mutations associated with drug resistance
Nonresponders
I-resistanceb NRTI-resistancea NNRTI-resistanceb
2 6 0
3 1 6
2 1 2
1 0 0
0 215 219), ddI (65 74 75 184).
103 106 108 181 188 190).ABLE 3
ce aga
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NNRT
70 21ressure is imposed (Table 4). At baseline, the majority
o
a
1
c
v
p
1
s
m
d
p
m
c
r
s
p
s
w
t
s
t
s
s
p
1
c
v
i
s
r
t
c
t
p
t
v
t
E
t
s
w
n
e
m
t
o
(
a
a
r
e
s
s
o
c
a
s
S
A
W
W
W
W
n
o h the s
161SELECTION PRESSURE AND HIV polf viruses represent ‘‘master sequences’’ best adapted to
nd therefore most fit under those conditions (Chao,
990; Najera et al., 1995). When selective pressure by a
hange in drug therapy was applied, minor preexisting
ariants, better adapted to the new environment, dis-
laced the former dominant quasispecies (Havlir et al.,
996). Sequence changes after week 8 likely repre-
ented acquisition of de novo mutations, and viral fitness
ay have been largely restored by that time so that
istances increased only slowly. For example, the pro-
ortion of patients with isolates carrying the Y181C point
utation associated with nevirapine resistance in-
reased modestly from week 8 (31%) to 48 (53%).
Positive selection pressure is generally thought to be
eflected in protein coding changes. The finding in this
tudy of more nonsynonymous changes in the RT of
atients under strong selection pressure (strong re-
ponders) than in the nonresponders is in agreement
ith this conventional view. However, we also encoun-
ered a significantly higher number of synonymous sub-
titutions in the RT of strong responders. This observa-
ion could be explained by Coffin’s assertion that no base
ubstitution, whether synonymous or nonsynonymous
hould be considered ‘‘neutral’’ when occurring in viral
opulations with a very high replication rate (Coffin, 1992,
995). The view that the large number of synonymous
hanges observed in this study may indeed contribute to
iral fitness is reinforced by the observation that the
ncidence of mutations associated with drug resistance
een at week 8 was similar among strong and non-
T
Relationships between Nonsynonymous (pn) and Sy
Groups of sequences
No. of
sequences
Ratios p n/p s
HIV-1
pol
HIV-1
protease
ll sequences 73 0.26 0.26
eek 8 32 0.22 0.25
eek 48 41 0.35 0.26
eek 8
25% with greatest RNA
decrease
8 0.23 0.28
25% with greatest RNA
increase
8 0.19 0.12
(7)a (0.23)a (0.23)a
eek 48
25% with greatest RNA
decrease
11 0.36 0.29
25% with greatest RNA
increase
11 0.38 0.25
Note. Ratios were generated for HIV-1 pol (1023 nucleotides) and sep
ucleotides) by dividing the mean of evolutionary distances for nonsyn
a Ratios and evolutionary distances calculated when one patient was
f synonymous substitutions in the protease gene than the patient witesponders. The RT-specific, positive correlation be- wween RNA response and the number of synonymous
hanges found in the patients at week 8 further supports
his interpretation.
An alternative explanation for the emergence of dis-
roportionately high numbers of synonymous substitu-
ions in the group under strong selection is a shift in the
iral population toward subpopulations produced in pro-
ected compartments like the CNS or the genital tract.
volution of HIV may differ considerably among ana-
omic compartments because of different selection pres-
ures (e.g., drugs, CTL-response) (Wong et al., 1997c).
Differential evolution between PR and RT was found
hen selection pressure was imposed on one gene but
ot on the other. In the absence of selection pressure, an
quivalent frequency of synonymous and nonsynony-
ous substitutions would be expected to accumulate in
hose two adjacent genes over time because mutations
ccur and become fixed at random (neutral evolution)
Coffin, 1995). Indeed, evolutionary distances for the PR
nd the RT gene were comparable in the nonresponders
t week 8 in whom we infer little or no selective pressure
elated to drug therapy (Fig. 5). In contrast, in patients
xperiencing stronger selection pressure (the strong re-
ponders), the gene under selection (RT) demonstrated
ignificant synonymous and nearly significant nonsyn-
nymous changes, whereas the PR gene did not. In this
ircumstance, the virus may optimize fitness by keeping
PR structure as ‘‘wild-type-like’’ as possible, while the
tructure of its RT adapts to the new selective forces.
uch an interpretation would be particularly consistent
ous Substitutions (ps) Expressed as Ratios (pn/ps)
Mean evolutionary distances
1
HIV-1 pol HIV-1 protease HIV-1 RT
pn ps pn ps pn ps
0.007 0.027 0.005 0.019 0.009 0.03
0.006 0.027 0.005 0.02 0.007 0.03
0.009 0.026 0.005 0.02 0.01 0.03
0.007 0.031 0.005 0.018 0.008 0.037
0.004 0.016 0.003 0.025 0.004 0.012
(0.013)a (0.013)a
0.009 0.025 0.005 0.017 0.012 0.029
0.008 0.021 0.005 0.02 0.01 0.023
for the protease (297 nucleotides) and reverse transcriptase (n 5 726
us substitutions (mean EDn) by the mean EDs
ed from analysis who had an unexplainable seven-fold higher number
econd highest number.ABLE 4
nonym
HIV-
RT
0.3
0.23
0.33
0.22
0.33
0.41
0.43
arately
onymo
excludith our observations that synonymous mutations may
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162 GU¨NTHARD ET AL.ot be completely neutral. Recombination could account
or such a linkage of wild-type PR and altered RT genes.
Recombination has been shown to occur in vitro by
everal groups (Coffin, 1992; Temin, 1993; Gu et al., 1995;
ellam and Larder, 1995; Moutouh et al., 1996; Yusa et al.,
997) and has been postulated to play a role in the
mergence of multiple drug resistant virus in vivo. Inter-
nd intraclade recombinations have also been demon-
trated to occur in vivo (Sabino et al., 1994; Diaz et al.,
995; Louwagie et al., 1995; Zhu et al., 1995; McCutchan
t al., 1996; Salminen et al., 1997). Recently Delwart et al.
xamined viral populations by heteroduplex mobility as-
ay in patients treated with PR monotherapy and found
ransient changes at the envelope locus arising early
fter initiation of therapy that waned when the suppres-
ive effect of the PR inhibitor was lost, suggesting that
ecombination occurred between the PR, conferring mu-
ations associated with drug resistance, and the base-
ine envelope gene that was probably better adapted to
he prevailing immune-selective pressures (Delwart et
l., 1998). An earlier report documented the independent
volution of the env and pol genes in patients treated
ith ZDV and also concluded that recombination be-
ween the two genes can occur (Leigh-Brown and Cle-
and, 1996). The fact that three independent studies,
ncluding this one, find evidence for the occurrence of
ecombination between different genes when one is un-
er selection pressure and the other one is not strength-
ns the argument that recombination is an important
lement in the response of HIV to escape from selection
orces in vivo; even more so, when one considers that
ifferent methodologies, different patient populations,
nd different drugs were used.
Natural history studies of evolution of different HIV-1
enes show pol to be one of the more conserved re-
ions. Env is the most variable gene of HIV-1 with a ratio
f nonsynonymous versus synonymous mutations of 0.44
Korber et al., 1995). For the matrix gag region this ratio is
0.4. In contrast, for the capsid-gag region, this ratio
alls to 0.15. For all 124 of HIV pol sequences examined
n our study, we calculated a ratio of 0.26 for HIV-pol,
onfirming the more conserved character of this gene.
owever, the term ‘‘conserved’’ in this context is relative
nd is clearly a function of selection pressures active
gainst the gene investigated. In our study, a substantial
ncrease of the pn/ps ratio for the RT gene (under selec-
ion pressure) occurred between week 8 (pn/ps 5 0.23)
nd week 48 (pn/ps 5 0.33), whereas the ratio for the PR
ene (not under selection pressure) remained un-
hanged (pn/ps 5 0.25, Table 4). Furthermore the toler-
nce of HIV-1 pol for sequence variation under selective
ressure has been underscored by recent reports de-
cribing stable codon insertions in the RT in subjects
reated with different nucleoside inhibitors (DeAntoni et
l., 1997; DeJong et al., 1998; Gu¨nthard et al., 1998b;
hitcomb et al., 1998; Winters et al., 1998). dAdditional alternative interpretations of the data from
his study should be considered. First, sequence varia-
ion of the PR could be more intrinsically constrained
han the RT and therefore could explain the greater
ivergence found in the RT. If this were the case, how-
ver, more substitutions would be expected in RT over
ime than were seen, independent of selection pressure
Fig. 5). Second, sampling could also account for the
reater divergence detected among strong responders.
ssuming that the viral population is small at the time
oint when sequences were obtained, the culture sys-
em might be biased by founder effects. However, in our
tudy even the strong responders did not have low
lasma levels at the time point when samples for se-
uencing were obtained. At week 8 the plasma levels
rom strong responders ranged from 4 to 5.5 log10, sug-
esting that cultures were obtained from a large popu-
ation size in all cases, rendering the likelihood of sam-
ling error minimal. Third, suppression of a master se-
uence within a mixed population could theoretically
esult in greater distances because of sampling different,
inority quasispecies. In such a scenario, however, dis-
ances between PR genes should be enhanced too,
hich was not the case. Fourth, because the strong
esponders had higher plasma HIV-1 RNA levels at base-
ine than did nonresponders, differences in baseline lev-
ls of replication alone might explain the differences in
equence divergence (Table 2). However, this simple
xplanation is inconsistent with the fewer substitutions
bserved between weeks 8 and 48 when plasma RNA
evels rebounded (Table 3) or with the differences in ED
oted for the RT and the PR (Fig. 5). Indeed both the
ignificantly greater reductions and the lower absolute
evels of plasma HIV RNA achieved by week 8 in strong
esponders suggest significantly less net replication in
his group during the period of study.
Sequences were derived from patients treated with a
ombination of RT inhibitors which typically results in
nly limited and unsustained reduction in plasma HIV-1
NA levels in nucleoside-experienced patients. In addi-
ion, sequences were generated from proviral DNA from
iral culture lysates, which may lead to underestimation
f the number of contemporaneous mutations in plasma
Delassus et al., 1991; Simmonds et al., 1991; Kusumi et
l., 1992; Michael et al., 1993; Gu¨nthard et al., 1998a).
oreover cultures were performed in the absence of
rugs, thus removing selection pressure on the RT,
hereas it was unchanged for the PR. Thus if divergence
as influenced by the culture system, this would have
ampened the difference in divergence seen between
R and RT rather than have increased it. Furthermore we
ave previously shown that high density oligonucleotide
equencing is relatively conservative with regard to call-
ng mutations from mixes of wild-type and mutant se-
uences (Gu¨nthard et al., 1998b). Taken together, the
ata set examined is likely to have resulted in underes-
t
o
o
p
p
s
w
a
n
v
h
a
R
s
o
p
s
s
a
d
P
f
e
T
t
(
e
c
a
a
a
e
w
4
(
s
u
t
V
f
(
w
l
a
f
w
l
G
a
P
3
A
R
r
P
A
s
p
m
2
i
f
1
1
m
s
G
E
S
a
(
t
C
b
A
h
(
T
(
b
a
a
c
t
N
h
a
V
q
l
t
t
163SELECTION PRESSURE AND HIV polimation of the true magnitude of the differences in some
f the comparisons performed.
In conclusion, this study reveals that HIV-1 pol dem-
nstrates considerable variability when under selection
ressure. Accelerated viral evolution of pol occurs in
atients under strong selection forces analogous to
tudies of natural history of HIV-1 env. The fact that there
as no difference detected in mutations known to be
ssociated with drug resistance between strong and
onresponders suggests that in addition to changes in
iral protein coding sequence, other mechanisms may
ave influenced viral fitness. The significantly higher
ccumulation of synonymous substitutions found in the
T of strong but not in nonresponders suggests that
uch nucleotide changes may not be completely neutral
r that the drugs used did not inhibit viral replication in
rotected sites. In addition, the data presented here
uggest that in vivo recombination linking RT adapted to
election pressures imposed by treatment with NNRTI
nd RTIs and wild-type PR could explain the greater
iversity found in RT than PR.
METHODS
atients
Sequencing of pol from HIV-1 viral isolates was per-
ormed on a subset of 51 of the original 398 patients
nrolled in the ACTG 241 study (D’Aquila et al., 1996).
his study compared the efficacy of the triple combina-
ion of zidovudine (ZDV), dideoxyinosine (ddI), nevirapine
NVP) vs ZDV, and ddI alone in nucleoside RT-inhibitor-
xperienced patients. Forty patients in this subset re-
eived NVP, ZDV, and ddI and 11 patients received ZDV
nd ddI only. Subjects from the double-combination-ther-
py arm studied here had prior therapy with only ZDV,
nd subjects on triple therapy studied here had received
ither ZDV alone or another nucleoside RT inhibitor as
ell. Sequences were available at baseline, weeks 8 and
8 (n 5 22 patients), or at baseline and either week 8
n 5 10 patients) or 48 (n 5 19 patients). Overall, 124
equences with corresponding plasma HIV-1 RNA val-
es were available for sequence analysis and correla-
ion to RNA levels.
irus isolation
PBMC (1 3 106) were cocultured with 1 3 106 unin-
ected donor PBMC according to a standard protocol
Jackson et al., 1990). A quantitative microculture assay
as performed, and infectious virus titers were calcu-
ated (Myers et al., 1994). After pooling of wells and
ddition of fresh donor PBMC, cells and supernatant
luids were harvested and frozen. These ‘‘mini-stocks’’
ere used to infect new donor PBMC and cells wereysed for PCR 7 days after infection. ceneration of target nucleic acid for sequence
nalysis
A 1.2-kb DNA fragment of HIV-1 pol was amplified by
CR from culture lysates under the following conditions:
9 inside primer PRO-RT39: 59-GTAATACGACTCA-CTAT-
GGGCCACTaagcttCTGTATGTCATTGACAGTCCA-39 (T7
NA polymerase promoter sequence in italics, HindIII
estriction site in lower case) and 59 inside primer
RO-RT59: 59-AATTAACCCTCACTAAAGggatccAGACCAG-
GCCAACAGCCCCA-39 (T3 RNA polymerase promotor
equence in italics and BamHI in lower case) (0.25
mol/ml each)). An initial denaturation step at 94°C for 2
in was followed by 35 amplification cycles (95°C for
0 s, 65°C for 40 s, 72°C for 45 s), followed by an
ncubation at 72°C for 10 min. Reagents were used as
ollows: rTth DNA polymerase (0.04 U/mL), 3.33 XL Buffer
3, respectively, 0.73, Mg(0Ac)2 (2.5 mM, respectively,
.5 mM) (all Perkin–Elmer, Foster City, CA) dNTPs (0.2
M each). The total reaction volume was 50 ml for each
tep (40 ml PCR reagent mix and 10 ml viral lysate). A
ene AMP PCR System 9600 thermocycler (Perkin–
lmer) was used.
equence analysis by high-density oligonucleotide
rrays
The method has been described in detail elsewhere
Gu¨nthard et al., 1998b) Briefly, cDNA amplicons were
ranscribed with T3/T7 RNA polymerases (Promega
orp., Madison, WI) in the presence of fluorescein-la-
eled rUTP (Boehringer Mannheim) to generate cRNA.
fter a fragmentation step, the RNA fragments were
ybridized to the PRT 440 sense and antisense chips
Affymetrix) according to the manufacturer’s procedure.
he chip was scanned by a confocal laser microscope
Affymetrix, St. Clara, CA). A composite sequence of 1023
p of HIV-1 pol was generated by integrating the sense
nd the antisense chip data using the ‘‘consensus rules
lgorithm’’ (GeneChip 2.0 software, Affymetrix). This in-
ludes the entire PR region (codons 1–99) and 726 bp of
he RT Region (codons 1–242).
ucleotide sequence accession numbers
Complete sequences of viral genes from 51 patients
ave been sent to GenBank (sequences will be available
t GenBank within six months of this publication).
iral quantification
At baseline, week 8 and week 48 HIV plasma RNA was
uantified with the Amplicor Monitor assay (Roche Mo-
ecular Systems, Branchburg, NJ) according to manufac-
urer’s specifications. Responders were defined as pa-
ients who had an RNA decrease; nonresponders had no
hange or an increase of plasma HIV-1 RNA.
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164 GU¨NTHARD ET AL.volutionary distances
Evolutionary distances (ED) were calculated from
aseline to week 8 and from baseline to week 48. The
roportion of synonymous substitutions per synonymous
ite (ps) and of nonsynonymous (pn) substitutions per
onsynonymous site were calculated from inferred pro-
ein coding sequences using MEGA version 1.01 (Jukes-
antor distance). ED were generated for the total of 1023
ucleotides of HIV-1 pol sequenced and separately for
he 297 nucleotides of the PR gene and for 726 nucleo-
ides of the RT gene. In addition, ED were also calculated
or nucleotide substitution comparisons using Phylip 3.5
Kimura’s 2-parameter distance, transition/transversion
atio 1.4). Phylogenetic trees (data not shown) were gen-
rated using a neighbour-joining method with 100 boot-
trapped data sets and using a maximum-likelihood
ethod.
atio of nonsynonymous/synonymous substitutions
pn/ps)
Ratios were calculated by dividing means of EDn by
Ds.
tatistics
Means of ED and of RNA responses (baseline value to
ither week 8 or 48) were compared with the ANOVA and
tudent’s t test for each pair. To normalize the distance,
alues log10 and squareroot transformations were per-
ormed. Correlations were calculated by the least-square
ethod and all statistical analyses were performed us-
ng the JMP 3.51 software package (SAS Institute Inc.,
ary, NC).
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